Dr. Reddys Laboratories Ltd.
BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1234.60
-10.90 (-0.88%) Dr. Reddy's seeks DCGI nod to conduct phase-3 clinical trial of Russian COVID-19 vaccine Sputnik V
Date: 03-10-2020Dr. Reddy's Laboratories has applied to the Drugs Controller General of India (DCGI) for permission to conduct phase-3 human clinical trials of the Russian vaccine Sputnik V against COVID-19 in India. The Indian pharma giant has collaborated with The Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V as well as its distribution.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.